Top 30 Drugs By Global Sales In 2024
Global Pandemic COVID-19 has turned the fate of many international pharmaceutical companies by paving way for their successful increase in sales revenues. But at the same time, number of pharmaceutical enterprises faced dramatic down in their long term selling reign as the world's priority was totally shifted towards eliminating the different variants of Coronavirus.
The new year of 2023 is thus graciously welcomed as an indicator of the end of COVID-19. Now, the change in top 30 drugs by global sales in 2023 can be clearly understood by the data given below. To know about these top-selling drugs make sure you have gone through the underlying information!
| Rank | Drug Name | Company | Sales |
| 1 | Keytruda | Meri & Co | $24 billion |
| 2 | Comirnaty | Pfizer | $19 billion |
| 3 | Humira | AbbVie | $13.5 billion |
| 4 | Paxlovid | Pfizer | $13 billion |
| 5 | Eliquis | BMS/Pfizer | $13 billion |
| 6 | Opdivo | BMS/Ono Pharmaceutical | $11.5 billion |
| 7 | Dupixent | Sanofi | $11 billion |
| 8 | Stelara | Johnson & Johnson, Mitsubishi | $11 billion |
| 9 | Spikevax/Covid-19 vaccine | Moderna | $11 billion |
| 10 | Biktarvy | Gilead | $11 billion |
| 11 | Imbruvica | AbbVie, Johnson & Johnson | $9.8 billion |
| 12 | Trikafta/Kaftrio | Vertex Pharmaceuticals | $9 billion |
| 13 | Eylea | Regeneron Pharmaceuticals, Bayer | $8 billion |
| 14 | Darzalex | Johnson & Johnson | $8 billion |
| 15 | Xarelto | Bayer, Johnson & Johnson | $7 billion |
| 16 | REGEN-COV/Ronapreve | Regeneron, Roche | $7 billion |
| 17 | Gardasil 9 | Merck | $6.9 billion |
| 18 | Trulicity | Eli Lilly | $6.5 billion |
| 19 | Veklury | Gilead Sciences | $6.4 billion |
| 20 | Prevenar 13 | Pfizer and Daewoong Pharmaceutical | $6 billion |
| 21 | Tagrisso | AstraZeneca | $5.8 billion |
| 22 | Entyvio | Takeda Pharmaceutical | $5.4 billion |
| 23 | Perjeta | Roche and Shugai Pharmaceutical | $4.9 billion |
| 24 | Cosentyx | Novartis | $4.8 billion |
| 25 | Xtandi | Astellas and Pfizer | $4.7 billion |
| 26 | Soliris | AstraZeneca & Alexion Pharmaceutical | $4.3 billion |
| 27 | Enbrel | Amgen and Pfizer | $4 billion |
| 28 | Ibrance | Pfizer | $3.3 billion |
| 29 | Invega Sustenna & Invega Trinza | Johnson & Johnson | $2.5 billion |
| 30 | Ocrevus | Roche | $1.5 billion |
1.Keytruda
Company: Merck & Co
Sales: $24 billion
Description
Keytruda is a type of immunotherapy drug used for preventing certain types of cancers such as lung cancer, breast cancer, cervical cancer and others. It is slowly infused in body through injection. Merck Corporation is the producer of this influencial drug which has generated $24 billion sales in 2023 and contributing to the total 40% of Company's pharmaceutical segment revenue.
2.Keytruda
Company: Pfizer
Sales: $19 billion
Description
Comirnaty is a type of monovalent vaccine used for curing CORONAVIRUS dieses. This vaccine is adopted for individuals of age 12 and over. Under the administration of Pfizer, Comirnaty has added much to the company's overall revenue by producing sales of $36 billion in 2021, $37 billion in 2022 and $19 billion in 2023.
3.Humira
Company: AbbVie
Sales: $13.5 billion
Description
AbbVie is United States' top famous biomedical company known for its discoveries of innovative medicinal treatment. Among them, Humira injection pen is most popular for holding prescribed medicine. The Humira injection pen contains two dosage of liquid that prevent moderate to severe inflammatory symptoms in adults including rheumatoid arthritis and Pediatric Ulcerative Colitis. For past decade, the sudden rise of $2 billion sales in each year has been noticed which is still continued.
4.Paxlovid
Company: Pfizer
Sales: $13 billion
Description
Paxlovid is a type of oral dosage formed by the combination of two antiviral medications. The solution is secured by Pfizer in form of tablets, for combating new variant of Coronavirus named omicron. Its highly rapid effects have resulted in the unexpected boost to Pfizer sales revenue by surprising sales of $18.9 billion in 2022 and $13 billion in 2023.
5.Eliquis
Company: BMS/Pfizer
Sales: $13 billion
Description
The collaboration of two competitors BMS and Pfizer is no doubt can be seen in bright outcomes, the drug Eliquis displayed. Having been anticoagulant medication, Eliquis is effectively preventing certain types of blood clotting. Eliquis is a form of oral dosage approved by FDA, which has shown remarkable sales in recent years by uplifting the revenue of both manufacturers $9 billion and $3 billion respectively.
6.Opdivo
Company: BMS/Ono Pharmaceutical
Sales: $11.5 billion
Description
Opdivo is a prescribed dosage in form of injection water. It is particularly prepared to destroy the cells of kidney cancer, stomach cancer, esophageal cancer and gastric cancer. After the fluctuation in 2020, a rise in the sale of Opdivo has seen in recent two years. The estimates further show that both BMS and Ono Pharmaceutical are going to generate $11 billion revenue through Opdivo sales.
7.Dupixent
Company: Sanofi
Sales: $11 billion
Description
Dupixent is an injectable medication brought by Sanofi to treat the serious inflammation that may create rash, redness and itching. Approved by FDA, European Commission and dermatologists, Dupixent is now okay for children over 6 months. Along with that certain other benefits of improving sleep, reduction in skin pain and zero side effects are associated with Dupixent. This is the reason for its high demand as a result of which its revenue exceeded $11billion.
8.Stelara
Company: Johnson & Johnson
Sales: $11 billion
Description
Stelara was introduced in 2009 by Janssen Pharmaceuticals, to defeat the serious and painful disease of psoriasis, Crohn's disease and psoriatic arthritis. By entering the market, Stelara sales were increasing with rise of 20% seen in three consecutive years starting from 2020. Currently, this drug of Johnson & Johnson is facing a little down due to AbbVie's Humira used for same disease. However, the drug is expected to encompass the sales revenue of near $11 billion in 2023.
9.Spikevax/Covid-19 vaccine
Company: Moderna
Sales: $11 billion
Description
Moderna's Spikevax is a vaccine used for strengthening immune system to fight against COVID-19 infection. Moderna boosted its economy by generating near $40 billion sales revenue in just past two years. This uplifting sales has faced a slump in 2023 with reduction in Coronavirus disease. Despite falling the sales, Moderna is forecasting to secure $11 billion revenue in the running year.
10.Biktarvy
Company: Gilead
Sales: $11 billion
Description
Biktarvy is an antiviral fixed-dose medication, indicated for the treatment of most dreadful illness of HIV/AIDS. Study shows, that it lowers the presence of HIV in human body and help them in minimizing HIV complications. Its manufacturer Gilead has gained probably the highest revenue up till now by the sudden increase in HIV cases and also the prices of drug contributed to it. Gilead declared, its sales of Biktarvy has been increased by 20% in 2022 following the same frequency with a 1% rise in 2023 by getting $11 billion sales revenue.
11.Imbruvica
Company: AbbVie, Johnson & Johnson
Sales: $9.8 billion
Description
AbbVie and Johnson & Johnson's Imbruvica is a prescribed oral dosage in form of capsules. Approved by FDA Imbruvica is indicated to be taken by adults for curing hematologic cancers and Waldenström's macroglobulinemia (WM). Having presence in over 95 countries, Imbruvica is continuously delivering fruitful outcomes for the efforts of both manufacturers by giving surprisingly sales of near $10 billion.
12.Trikafta/Kaftrio
Company: Vertex Pharmaceuticals
Sales: $9 billion
Description
As the name indicates, Trikafta is the mixture of three distinct compounds tezacaftor, elexacaftor and ivacaftor. It is primarily used for cystic fibrosis, a rare genetic pulmonary disorder. When it comes to the top seller of Trikafta, global sights stood at Vertex Pharmaceuticals, who generate about $8.2 billion in 2022 by selling this drug alone. Looking ahead, Vertex Pharmaceuticals is determined to cross the figure $9 billion in 2023.
13.Eylea
Company: Regeneron Pharmaceuticals, Bayer
Sales: $8 billion
Description
Regeneron Pharmaceuticals and Bayer is doing constant efforts to keep the value of Eylea on same position despite the new formulas introduced by growing competitors. The effective drug of Eylea is a type of liquid medication infused in eyes through injection. Eylea is primarily indicated to treat wet age-related macular degeneration (AMD). Eylea has generated $8.9 billion sales revenue in 2021 that was dropped by 3% in 2022 with 8% billion. The same is expected for running year 2023.
14.Darzalex
Company: Johnson & Johnson
Sales: $8 billion
Description
Darzalex is the world's first ever drug launched for the treatment of multiple myeloma. It can be also used for treating other diseases by combination with different formulas. Darzalex is Johnson & Johnson's second most popular drug used on large scale. A positive shift was seen in sales revenue of Darzalex last year which increased from $7 billion in 2021 to $8 billion in 2022 and the same is continued for 2023.
15.Xarelto
Company: Bayer, Johnson & Johnson
Sales:$7 billion
Description
Xarelto by Bayer and Johnson & Johnson is an anticoagulant medication launched for intelligently treating the disease of blood clotting in adults. The drug remained an upward trajectory throughout pandemic, but the circumstances changed abruptly in the last quarter of 2022. Yet, it has the potential to stood at the area and reach $7 billion sales in 2023.
16.REGEN-COV/Ronapreve
Company: Regeneron, Roche
Sales: $7 billion
Description
In 2020, U.S. Food and Drug Administration has approved REGEN-COV to be used on emergency basis for adult patients older than 12 years having positive result for COVID-19. The vaccine delivered remarkable sales in 2020 and 2021 with $7.5 billion revenue. Later, with the development of new and proper vaccines, its revenue fell from 1.14 billion euros to 1.9 billion euros.
17.Gardasil 9
Company: Merck & Co.
Sales: $6.9 billion
Description
Gardasil 9 is a vaccine prepared for the elimination of 9 types of Human papillomavirus HPV, common sexually transmitted diseases especially among women. It was developed by Merck & Co. in 2014 which was soon welcomed internationally; however, the rise of pandemic diverted the world's attention towards COVID-19 vaccines. But now, Gardasil 9 has backed to its position as countries are focused on preventing routine viruses. That's how, the growth of Gardasil 9 sales increased by 22% in 2022 with $6.9 billion revenue and company is ambitious to further increase this figure.
18.Trulicity
Company: Eli Lilly
Sales: $6.5 billion
Description
Trulicity GLP-1 agonist is an injectable medication brought by Eli Lilly for curing type-2 diabetes and normalizing blood sugar. It is one of the Eli Lilly's top drugs having high contribution in uplifting the company's overall revenue. Trulicity's sales, serve as a good indicator of this trend, which increased from $5 billion in 2020 to $7 billion in 2022. The company is expecting same for future.
19.Veklury
Company: Gilead Sciences
Sales: $6.4 billion
Description
Veklury is a type of COVID-19 vaccination introduced by Gilead Sciences. It was employed to be used for adults in general and children with at least age of 4 weeks in particular. Gilead Sciences' has captured international attention for its effective and affordable dose of COVID-19 vaccine. Up till now, Veklury has added up to $15 billion revenue to Gilead by its sales.
20.Prevenar 13
Company: Pfizer and Daewoong Pharmaceutical
Sales: $6 billion
Description
Prevenar 13 is a single-dose prefilled syringe that is injected into body for preventing pneumococcal disease in adults and children with over 5 years. Pfizer and Daewoong Pharmaceutical collaborated for manufacturing this drug, which in turn has contributed to give high revenue from past 3 years. Recently, both companies are forecasting to carry the figure of $6 billion in 2023 on part of Prevenar 13 sales.
21.Tagrisso
Company: AstraZeneca
Sales: $5.8 billion
Description
Tagrisso is a type of film-coated tablets particularly prepared for treating lung cancer and associated disorder. It is low in dosage, that's why most of the doctors allow patients to take it by their own whenever they feel abnormal epidermal growth. Tagrisso generated brilliant sales revenue of $5.4 billion in 2022 for AstraZeneca and the company has declared the rise in it by mentioning figure of $5.8 billion for 2023.
22.Entyvio
Company: Takeda Pharmaceutical
Sales: $5.4 billion
Description
Entyvio is one of the Takeda Pharmaceutical's top drugs launched in 2014. The drug is indicated for the treatment of moderate to severe ulcerative colitis or Crohn's disease. Takeda has received around $5.4 billion sales revenue from Entyvio in 2023. Its sales is further projected above $5.4 in 2023.
23.Perjeta
Company: Roche and Chugai Pharmaceutical
Sales: $4.9 billion
Description
Perjeta is the prime medication brought by Roche in 2012 to target the rising cases of breat cancer among women. Later with the assistance from Chugai Pharmaceutical both enterprises joined hands to work collectively, and resultantly they have seen a surprising boost in Perjeta revenue which increased from $3.9 billion to $4.9 billion in 2013.
24.Cosentyx
Company: Novartis
Sales: $4.8 billion
Description
Novartis approved Cosentyx by FDA in 2014 as a first ever human biologic medication for Plaque psoriasis, active psoriatic arthritis and active ankylosing spondylitis. The efficiency and demand of this drug has thus pushed its sales from all over the world, and now it is considered among world's top-selling drugs with $4.8 revenues.
25.Xtandi
Company: Astellas, Pfizer
Sales: $4.7 billion
Description
Based in Tokyo, Japan, Astellas is a reputable pharmaceutical company dedicated to revitalize the existing medicine formulas by innovation. In 2021, Pfizer became a partner of Astellas for the project of Xtandi capsules to resist prostate cancer. Consequently, the project became successful and generated about $4.7 billion sales revenue in 2023.
26.Soliris
Company: AstraZeneca and Alexion Pharmaceuticals
Sales: $4.3 billion
Description
Alexion Pharmaceutical is the original developer of Soliris, a drug for curing the disease of Paroxysmal Nocturnal Hemoglobinuria and Hemolytic Uremic Syndrome. In July 2021, AstraZeneca came to an agreement with Alexion and got up to $4.1 billion sales revenue in 2022. The owners of Soliris are estimating further increase in its existing sales with giving ratio of $4.3 billion.
27.Enbrel
Company: Amgen and Pfizer
Sales: $4 billion
Description
Enbrel is a type of prescribed medication available in form of injection. It is adopted for the minor symptoms or severe rheumatoid arthritis (RA) disease. However, the drug may badly affect the immune system of patient taking it. The two partners Amgen and Pfizer are still having positive estimates about the future sales revenue of $4 billion in part of Enbrel.
28.Ibrance
Company: Pfizer
Sales: $3.3 billion
Description
Pfizer developed a prescription medication Ibrance to treat the diseases of HR+, HER-2 and breast cancer in women and men. In 2015, Ibrance was quite popular and had good demand. However, it was later competed by Eli Lilly and Novartis with same drug. Currently, the company is generating $3.3 billion of its sales revenue by selling Ibrance.
29.Invega Sustenna and Invega Trinza
Company: Johnson & Johnson
Sales: $2.6 billion
Description
Invega Sustenna and Invega Trinza can be better defined as two faces of the same coin. It is due to their association with similar treatment of schizophrenia; first by Invega Sustenna for 6 months followed by Invega Trinza. This perfect combination is brought by Johnson & Johnson which was warmly welcomed by international pharmacies. As a result, a big rise of $2.6 billion revenue was achieved in short period.
30.Ocrevus
Company: Roche
Sales: $1.5 billion
Description
Roche's Ocrevus has seen applausable growth despite the growing competitors and waves of pandemic. It was launched to cure certain forms of primary progressive multiple sclerosis in adults. It shows rapid effects by slowing down symptoms of the disease. Thus, Roche is proud of this effective drug creation that has added about $1.5 billion sales revenue to its income.
Conclusion
We hope, this article demonstrated a clear picture of top 30 drugs by global sales in 2023. Research has shown, that above top 30 drugs are contributing on a larger scale to the overall revenue of their manufacturers. All these drugs are approved by U.S. Food and Drug Administration and have undergone various clinical trials to be of good quality. Was this information helpful for you? If yes! You should never miss a chance to know similar content. Just be in contact with us for knowing more.
Don't forget to share this post!
Vial Filling Machine Related Posts
Vial Filling Machine Related Products
Vial Filling Machine Related Videos
CONTACT US
Tell us your raw material and project budget to get quotations within 24 hours.
WhatsApp Us: +86 189 7157 0951
Want the best price & newest pharmaceutical machinery buying guide,tips and trends sent straightly to your box?Sign up for AIPAK’s monthly newsletter,we’re free for your consultation and Offer you the most suitable solutions!
The Buyer's Guide
- Capsule Filling Buyer's Guide
- Blister Packaging Buyer's Guide
- Tablet Counting Buyer's Guide
- Tube Filling Buyer's Guide
- Cartoning Buyer's Guide
- Gummy Making Buyer's Guide
- CO2 Extraction Buyer's Guide
- Empty Capsules Buyer's Guide
- Suppository Filling Buyer's Guide
- Tablet Coating Buyer's Guide
- Tablet Press Buyer's Guide
- Softgel Encapsulation Buyer's Guide
Most Popular
- 7 Importance Of Pharmaceutical Packaging In Different Applications You Must Know
- 6 Advantages You Must Know About Tablet Counting Machine
- 8 Advantages of Blister Packaging You Must Know
- 6 Critical Applications of Automatic Capsule Filling Machine
- 6 Stations You must Know to Improve the Filling Quality of Automatic Capsule Filling Machine
Tell us your material or budget, we'll reply you ASAP within 24 hours